Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.54, while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCIT | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $84.82 | $164.28 |
52-Week Low | $81.45 | $85.16 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
